Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25240043 | 1.00 | CRBN (0.49) | CRBNDDB1IKZF3PRKAB2PRKAG1 | |
| SCHEMBL30985168 | 0.84 | CRBN (0.49) | CRBNDDB1IKZF3 | |
| SCHEMBL25249148 | 0.82 | CRBN (0.42) | CRBNDDB1 | |
| SCHEMBL31161726 | 0.81 | DDB1 (0.50) | CRBNDDB1IKZF3 | |
| SCHEMBL28978035 | 0.81 | DDB1 (0.44) | CRBNDDB1 | |
| SCHEMBL30984703 | 0.81 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL25575969 | 0.79 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL29277065 | 0.78 | CRBN (0.54) | CRBNDDB1 | |
| SCHEMBL27119032 | 0.77 | CRBN (0.68) | CRBNDDB1 | |
| SCHEMBL23115228 | 0.76 | DDB1 (0.44) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115244053-B | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-115710274-A | IRAK4 degradation agent, preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-115244053-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CRBN 221/4885DDB1 1973/4885IKZF3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.